The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.19
High: 0.00
Low: 0.00
Prev. Close: 0.19
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: De La Rue Down As CEO Exits And Profit Falls

Thu, 30th May 2019 10:33

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - LOSERS----------National Grid, down 4.7%, Marks & Spencer, down 4.3%. The stocks went ex-dividend meaning new buyers no longer qualify for the latest payout. ----------Johnson Matthey, down 3.5%. The speciality chemicals firm upped its annual payout following a sharp increase in profit but said growth will be slower next year due to plans for significant investment. "We anticipate that these investments for growth and efficiency will lead to a slightly lower margin than in 2018-19," the company said. Johnson Matthey reported 53% growth in pretax profit to GBP488 million in the financial year that ended on March 31 compared to GBP320 million reported the year earlier, as revenue rose 4.6% to GBP10.75 billion from GBP10.27 billion. Profit was slightly short of market expectations. According to company-compiled consensus figures for financial 2019, pretax profit was expected to jump 56% to GBP500.7 million. Johnson Matthey declared a final dividend of 62.25 pence a share, taking the total payout for the year to 85.5p, up 6.9% from 80.0p paid the year before. Looking ahead, Johnson Matthey said it expects foreign exchange movements in the financial year to the end of March 2020 to hurt sales and underlying operating profit by GBP6 million and GBP2 million, respectively.----------FTSE 250 - WINNERS----------FirstGroup, up 5.5%. The transport operator unveiled a new strategy which will see the sale of the transport operator's North American intercity coach operation, Greyhound, as well as separation of its UK bus business, First Bus. The company said it has started the sale process for Greyhound as the unit has "limited synergies" with the rest of the company's operations. For the same reason, FirstGroup plans to separate First Bus from its UK operations. Going ahead, North America will be the firm's core market with emphasis on First Student and First Transit, which together generated 60% of group operating profit in 2019 and "have the greatest potential to generate sustainable value and growth over time". Separately, the company reported a narrowed pretax loss for the year ended March to GBP97.9 million from GBP326.9 million. Revenue for the year rose 11% to GBP7.13 billion from GBP6.40 billion. Looking ahead, FirstGroup said it expects to deliver revenue growth and financial progress in its Road divisions in financial 2020, with adjusted earnings guided "broadly in line with expectations". Spreadex analyst Connor Campbell said: "Beyond replacing the CEO and board, this basically ticks off most of the demands Coast Capital had been making, and was clearly popular with investors,"----------Tullow Oil, up 3.5%. Goldman Sachs promoted the oil and gas company to its Conviction Buy List.----------FTSE 250 - LOSERS----------Computacenter, down 1.7%. The stock went ex-dividend.----------Babcock International, down 1.6%. Goldman Sachs downgraded the engineering services firm to Neutral from Conviction Buy. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Nuformix, up 37%. The pharmaceutical development company reported positive results in its clinical study of NXP001. The company explained that NXP001 is being developed as a treatment for chemotherapy-induced nausea and vomiting, occurring in a third of cancer patients worldwide. In a pilot study conducted among healthy subjects, Nuformix's cocrystal-based formulation demonstrated bioequivalence to Merck's EMEND, the currently used treatment for nausea and vomiting in chemotherapy, both in terms of peak and overall exposure. The positive results allow Nuformix to receive a final GBP2 million milestone payment form its Chinese licensing partner, Newsummit Biopharma, which has started product registration in China.----------BigDish, up 15%. The online reservation platform said it is now ready to start the larger UK roll out of its restaurant reservation app. The company's BigDish app is expected to go live in Brighton and Reading on June 7, following the successful launch in Swindon and Taunton. The app allows restaurant-goers to book a table and receive discounts. As it rolls the service out nationwide, Big Dish has divided the UK into ten territories. Each territory will have one manager with the exception of London, which will have three. BigDish expects the managers recruitment process to take between three and four months. The company now has over 150 restaurants on its platform, most of which independent. It said its roll out plans will initially target independent and smaller restaurant groups. ----------OTHER MAIN MARKET AND AIM - LOSERS----------De La Rue, down 31%. The banknote printer proposed a restructuring, after annual profit fell sharply and in preparation for the expiration of the company's UK passport contract. In addition, De La Rue said Martin Sutherland has agreed to step down as chief executive as soon as his successor is in place. The company has already commenced the recruitment process, it said. Pretax profit for the financial year ended March 30 dropped to GBP25.5 million from GBP113.6 million a year earlier, as operating expenses jumped to GBP533.3 million from GBP370.9 million. De La Rue declared a final dividend of 16.7 pence a share, unchanged from the prior year. This would make a full year payout of 25.0p per share, also unchanged. De La Rue proposed a reorganisation that is aimed at creating better strategic focus and greater efficiency, with a cost-cutting programme that will deliver in excess of GBP20 million annual savings by 2022. De La Rue intends to restructure its operations into two divisions: Authentication and Currency. ----------

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.